Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation

Loading news article.

Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation | WAPE

Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation

Article summary

Related companies

Comments —